Frontiers in Genetics (Aug 2024)

Preliminary effects of risk-adapted PSA screening for prostate cancer after integrating PRS-specific and age-specific variation

  • Xiaomin Liu,
  • Hongyuan Duan,
  • Siwen Liu,
  • Yunmeng Zhang,
  • Yuting Ji,
  • Yacong Zhang,
  • Zhuowei Feng,
  • Jingjing Li,
  • Ya Liu,
  • Ying Gao,
  • Xing Wang,
  • Qing Zhang,
  • Lei Yang,
  • Hongji Dai,
  • Zhangyan Lyu,
  • Fangfang Song,
  • Fengju Song,
  • Yubei Huang

DOI
https://doi.org/10.3389/fgene.2024.1387588
Journal volume & issue
Vol. 15

Abstract

Read online

BackgroundAlthough the risk of prostate cancer (PCa) varies across different ages and genetic risks, it’s unclear about the effects of genetic-specific and age-specific prostate-specific antigen (PSA) screening for PCa.MethodsWeighed and unweighted polygenic risk scores (PRS) were constructed to classify the participants from the PLCO trial into low- or high-PRS groups. The age-specific and PRS-specific cut-off values of PSA for PCa screening were determined with time-dependent receiver-operating-characteristic curves and area-under-curves (tdAUCs). Improved screening strategies integrating PRS-specific and age-specific cut-off values of PSA were compared to traditional PSA screening on accuracy, detection rates of high-grade PCa (Gleason score ≥7), and false positive rate.ResultsWeighted PRS with 80 SNPs significantly associated with PCa was determined as the optimal PRS, with an AUC of 0.631. After stratifying by PRS, the tdAUCs of PSA with a 10-year risk of PCa were 0.818 and 0.816 for low- and high-PRS groups, whereas the cut-off values were 1.42 and 1.62 ng/mL, respectively. After further stratifying by age, the age-specific cut-off values of PSA were relatively lower for low PRS (1.42, 1.65, 1.60, and 2.24 ng/mL for aged <60, 60–64, 65–69, and ≥70 years) than high PRS (1.48, 1.47, 1.89, and 2.72 ng/mL). Further analyses showed an obvious interaction of positive PSA and high PRS on PCa incidence and mortality. Very small difference in PCa risk were observed among subgroups with PSA (−) across different age and PRS, and PCa incidence and mortality with PSA (+) significantly increased as age and PRS, with highest risk for high-PRS/PSA (+) in participants aged ≥70 years [HRs (95%CI): 16.00 (12.62–20.29) and 19.48 (9.26–40.96)]. The recommended screening strategy reduced 12.8% of missed PCa, ensured high specificity, but not caused excessive false positives than traditional PSA screening.ConclusionRisk-adapted screening integrating PRS-specific and age-specific cut-off values of PSA would be more effective than traditional PSA screening.

Keywords